The SARS-CoV-2 main protease as drug target.

The SARS-CoV-2 main protease as drug target. Bioorg Med Chem Lett. 2020 Sep 01;30(17):127377 Authors: Ullrich S, Nitsche C Abstract The unprecedented pandemic of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is threatening global health. The virus emerged in late 2019 and can cause a severe disease associated with significant mortality. Several vaccine development and drug discovery campaigns are underway. The SARS-CoV-2 main protease is considered a promising drug target, as it is dissimilar to human proteases. Sequence and structure of the main protease are closely related to those from other betacoronaviruses, facilitating drug discovery attempts based on previous lead compounds. Covalently binding peptidomimetics and small molecules are investigated. Various compounds show antiviral activity in infected human cells. PMID: 32738988 [PubMed - in process]
Source: Bioorganic and Medicinal Chemistry Letters - Category: Chemistry Authors: Tags: Bioorg Med Chem Lett Source Type: research

Related Links:

o-Wei Wei The transmission and evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are of paramount importance in controlling and combating the coronavirus disease 2019 (COVID-19) pandemic. Currently, over 15,000 SARS-CoV-2 single mutations have been recorded, which have a great impact on the development of diagnostics, vaccines, antibody therapies, and drugs. However, little is known about SARS-CoV-2’s evolutionary characteristics and general trend. In this work, we present a comprehensive genotyping analysis of existing SARS-CoV-2 mutations. We reveal that host immune response via APOB...
Source: Viruses - Category: Virology Authors: Tags: Article Source Type: research
Interim analysis from the ongoing Phase 1/2a clinical trial of the Janssen COVID-19 vaccine candidate (JNJ-78436735) was posted today on the pre-print server medRxiv.The data demonstrate that a single dose of JNJ-78436735 induced a strong neutralizing antibody response in nearly all participants aged 18 years and older and was generally well-tolerated. Immune responses were similar across the age groups studied, including older adults. The ongoing Phase 1/2a clinical trial is designed to study the safety and immunogenicity of two dose levels of the Janssen COVID-19 vaccine, and as single and two-dose schedules. The interim...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news
Authors: Mishra VN, Kumari N, Pathak A, Chaturvedi RK, Gupta AK, Chaurasia RN Abstract An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan City, China, in December 2019. Since then, the outbreak has grown into a global pandemic, and neither a vaccine nor a treatment for the disease, termed coronavirus disease 2019 (COVID-19), is currently available. The slow translational progress in the field of research suggests that a large number of studies are urgently required. In this context, this review explores the impact of bacteriophages on SARS-CoV-2, especially conce...
Source: International Journal of Microbiology - Category: Microbiology Tags: Int J Microbiol Source Type: research
David Brenner joins TWiV to explain how far-UVC lights could provide protection from SARS-CoV-2 and other airborne viruses in public places, solutions to face mask fogging, transmission during airplane flights, and listener questions. Click arrow to playDownload TWiV 666 (78 MB .mp3, 129 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Show notes at microbe.tv/twiv
Source: virology blog - Category: Virology Authors: Tags: This Week in Virology airborne inactivation airplane transmission coronavirus COVID-19 face mask far-UVC fogging pandemic SARS-CoV-2 UV light vaccine viral viruses Source Type: blogs
Authors: Madubueze CE, Dachollom S, Onwubuya IO Abstract Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS CoV-2). It was declared on March 11, 2020, by the World Health Organization as pandemic disease. The disease has neither approved medicine nor vaccine and has made governments and scholars search for drastic measures in combating the pandemic. Regrettably, the spread of the virus and mortality due to COVID-19 has continued to increase daily. Hence, it is imperative to control the spread of the disease particularly using nonpharmacological strategie...
Source: Computational and Mathematical Methods in Medicine - Category: Statistics Tags: Comput Math Methods Med Source Type: research
Authors: Chukwudozie OS, Chukwuanukwu RC, Iroanya OO, Eze DM, Duru VC, Dele-Alimi TO, Kehinde BD, Bankole TT, Obi PC, Okinedo EU Abstract The novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has previously never been identified with humans, thereby creating devastation in public health. The need for an effective vaccine to curb this pandemic cannot be overemphasized. In view of this, we designed a subcomponent antigenic peptide vaccine targeting the N-terminal (NT) and C-terminal (CT) RNA binding domains of the nucleocapsid protein that aid in viral replica...
Source: Journal of Immunology Research - Category: Allergy & Immunology Tags: J Immunol Res Source Type: research
Children have been relatively spared from the effect of clinical coronavirus disease 2019 (COVID-19). The newly described inflammatory syndrome is rare in terms of the total population of children, and severe acute forms of COVID-19 are even rarer in children and young people. Despite this, both experts and the public have struggled to come to terms with the fact that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is also different from all other known respiratory viral infections: there is significant uncertainty regarding children and young people ’s ability to catch, transmit, and spread the virus. W...
Source: JAMA Pediatrics - Category: Pediatrics Source Type: research
Abstract The coronavirus disease 2019 (COVID-19) pandemic presents an unprecedented threat to global public health. The spread of the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infections in a global scale has affected more than 30.6 million people suffering the COVID-19, resulting in more than 955,000 deaths globally as of the 20 September 2020. The current lack of specific and effective therapies for the COVID-19, and the continuous spread of coronavirus SARS-CoV-2 across many parts of the world, represent one of the major challenges in controlling the disease severity, keeping to pose a huge t...
Source: Clinical and Experimental Pharmacology and Physiology - Category: Drugs & Pharmacology Authors: Tags: Clin Exp Pharmacol Physiol Source Type: research
Coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), was declared a pandemic by the World Health Organization in March 2020. Severe COVID-19 cases develop severe acute respiratory syndrome, which can result in multiple organ failure, sepsis, and death. The higher risk group includes the elderly and subjects with pre-existing chronic illnesses such as obesity, hypertension, and diabetes. To date, no specific treatment or vaccine is available for COVID-19. Among many compounds, naringenin (NAR) a flavonoid present in citrus fruits has been investigated for antiviral and...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
The ongoing COVID-19 pandemic caused by infection with SARS-CoV-2 has created an urgent need for animal models to enable study of basic infection and disease mechanisms and for development of vaccines, therapeutics, and diagnostics. Most research on animal models for COVID-19 has been directed toward rodents, transgenic rodents, and non-human primates. The primary focus has been on the angiotensin-converting enzyme 2 (ACE2), which is a host cell receptor for SARS-CoV-2. Among investigated species, irrespective of ACE2 spike protein binding, only mild (or no) disease has occurred following infection with SARS-CoV-2, suggest...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
More News: Chemistry | Coronavirus | COVID-19 | Pandemics | Respiratory Medicine | SARS | Science | Vaccines